vimarsana.com

Latest Breaking News On - Ridgeback bio - Page 5 : vimarsana.com

Ridgeback Biotherapeutics Responds to 13th Ebola Outbreak in Democratic Republic of Congo

MIAMI (BUSINESS WIRE) Ridgeback Biotherapeutics (“Ridgeback Bio”), a biotechnology company experienced in antiviral drug development including medicines to treat SARS-Cov-2 and Ebola, announces deployment of the Ridgeback Ebola Rapid Response team to the Democratic Republic of the Congo (DRC). This deployment is an immediate response to the 13th outbreak of Ebola Virus…

Covid: Molnupiravir drugmaker Merck seeks marketing approval

Covid: Molnupiravir drugmaker Merck seeks marketing approval
sortiraparis.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sortiraparis.com Daily Mail and Mail on Sunday newspapers.

Natco Pharma seeks approval for Molnupiravir capsules for Covid-19 treatment

Natco Pharma seeks approval for Molnupiravir capsules for Covid-19 treatment PTI Hyderabad | Updated on American pharma major Merck along with Ridgeback Bio therapeutics has developed the drug Natco Pharma Limited on Monday said it applied to the Central Drugs Standard Control Organisation (CDSCO) for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of Covid-19 positive patients. American pharma major Merck along with Ridgeback Bio therapeutics has developed Molnupiravir(MK-4482). According to a press release from the city-based drug maker, pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients treated with Molnupiravir achieved response within 5 days of therapy indicating that the duration of treatment with Molnupiravir is short, with the additional advantage of being an oral therapy, it said.

Merck to continue Covid pill tests; admits no help for hospitalised patients

Merck to continue Covid pill tests; admits no help for hospitalised patients KENILWORTH, New Jersey, 2 hours, 39 minutes ago Merck (MSD) has said that it has seen “encouraging” results in a clinical trial of an anti-viral pill to treat Covid-19 early in the disease’s course, but the drug has failed to help hospitalised patients.   The company and its partner Ridgeback Biotherapeutics said they will stop Phase 3 trials on patients who have already been hospitalized with the disease.   The final data from the Phase 3 portion (Part 2) of the MOVe-OUT study is estimated to be available in September/ October 2021.    Based on a planned interim analysis of data from the Phase 2, dose-finding portion (Part 1) of two ongoing placebo-controlled Phase 2/3 trials evaluating molnupiravir administered twice a day for five days in outpatients (MOVe-OUT) and hospitalised patients (MOVe-IN) with Covid-19, and from a previously completed Phase 2a dose-ranging study in outpa

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.